Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Yu Pan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7417-4551; OpenAlex author ID A5017033667. Sources: OpenAlex.

Their work

Papers
17 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 4 papers · 2026: 1 paper

Papers 17

  1. SRSF1-DLAT axis drives mitochondrial fusion to confer therapy resistance in diabetes-associated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2026.101489↗
  2. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202508431↗
  3. Integrated transcriptome and single-cell RNA sequencing analysis revealed the prognostic significance of GBP4 in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102532↗
  4. Identification of prognostic and therapeutic biomarkers associated with macrophage and lipid metabolism in pancreatic cancer. Last author DOI 10.1038/s41598-025-99144-z↗
  5. TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. Co-author DOI 10.1158/0008-5472.can-24-4784↗
  6. Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. Last author DOI 10.1136/jitc-2024-009318↗
  7. Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor. Co-author DOI 10.1186/s12885-024-12193-x↗
  8. The cellular trajectories of tumor-associated macrophages decipher the heterogeneity of pancreatic cancer. Last author DOI 10.1007/s10142-023-01266-y↗
  9. High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fendo.2023.1181538↗
  10. Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer. Last author DOI 10.3389/fphar.2023.1193791↗
  11. Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer. First author DOI 10.3748/wjg.v28.i22.2468↗
  12. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. First author DOI 10.1007/s00432-020-03463-9↗
  13. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. First author DOI 10.1038/s41419-020-02787-1↗
  14. Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma First author DOI 10.1097/jp9.0000000000000055↗
  15. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Co-author DOI 10.1080/2162402x.2019.1581529↗
  16. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0822-6↗
  17. WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. Co-author DOI 10.1186/s13046-018-0848-6↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heguang Huang · 13 shared papers, 2018–2025 · strength 2.10
  2. Fengchun Lu · 9 shared papers, 2018–2024 · strength 1.28
  3. Xianchao Lin · 9 shared papers, 2018–2024 · strength 1.18
  4. Zelin Hou · 6 shared papers, 2019–2024 · strength 0.86
  5. Jiajing Lin · 4 shared papers, 2023–2024 · strength 0.79
  6. Zuwei Wang · 3 shared papers, 2025–2026 · strength 0.66
  7. Shi Chen · 3 shared papers, 2025–2026 · strength 0.66
  8. Wen Shi · 3 shared papers, 2023–2024 · strength 0.56
  9. Qinglin Fei · 5 shared papers, 2019–2021 · strength 0.53
  10. Ge Li · 2 shared papers, 2025–2026 · strength 0.46
  11. Minggui Pan · 4 shared papers, 2018–2023 · strength 0.44
  12. Cheng‐Yu Liao · 2 shared papers, 2025 · strength 0.40
  13. Haoxiang Zhang · 2 shared papers, 2025 · strength 0.40
  14. Shun‐Cang Zhu · 2 shared papers, 2025 · strength 0.40
  15. Yongding Wu · 2 shared papers, 2025 · strength 0.40
  16. Jianfeng Gao · 2 shared papers, 2022–2023 · strength 0.35
  17. Lili Wu · 1 shared paper, 2025 · strength 0.30
  18. Qiyu Chi · 1 shared paper, 2025 · strength 0.28
  19. Shangeng Weng · 1 shared paper, 2025 · strength 0.28
  20. Bohan Zhan · 1 shared paper, 2024 · strength 0.22
  21. Jianghua Feng · 1 shared paper, 2024 · strength 0.22
  22. Hong-Yi Lin · 1 shared paper, 2025 · strength 0.20
  23. Chengke Xie · 1 shared paper, 2025 · strength 0.20
  24. Ge Li · 1 shared paper, 2025 · strength 0.20
  25. Yifeng Tian · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.